232 related articles for article (PubMed ID: 16381666)
1. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers.
Ling J; Johnson KA; Miao Z; Rakhit A; Pantze MP; Hamilton M; Lum BL; Prakash C
Drug Metab Dispos; 2006 Mar; 34(3):420-6. PubMed ID: 16381666
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
Tan EY; Hartmann G; Chen Q; Pereira A; Bradley S; Doss G; Zhang AS; Ho JZ; Braun MP; Dean DC; Tang W; Kumar S
Drug Metab Dispos; 2010 Mar; 38(3):459-73. PubMed ID: 20016052
[TBL] [Abstract][Full Text] [Related]
3. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
[TBL] [Abstract][Full Text] [Related]
4. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
Prakash C; Cui D
Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans.
Smith BJ; Pithavala Y; Bu HZ; Kang P; Hee B; Deese AJ; Pool WF; Klamerus KJ; Wu EY; Dalvie DK
Drug Metab Dispos; 2014 May; 42(5):918-31. PubMed ID: 24608633
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.
Prakash C; Cui D; Baxter JG; Bright GM; Miceli J; Wilner K
Drug Metab Dispos; 1998 May; 26(5):448-56. PubMed ID: 9571226
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
[TBL] [Abstract][Full Text] [Related]
8. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.
Karanam B; Madeira M; Bradley S; Wenning L; Desai R; Soli E; Schenk D; Jones A; Dean B; Doss G; Garrett G; Crumley T; Nirula A; Lai E
Drug Metab Dispos; 2007 Jul; 35(7):1196-202. PubMed ID: 17431030
[TBL] [Abstract][Full Text] [Related]
9. Structural elucidation of human oxidative metabolites of muraglitazar: use of microbial bioreactors in the biosynthesis of metabolite standards.
Zhang D; Zhang H; Aranibar N; Hanson R; Huang Y; Cheng PT; Wu S; Bonacorsi S; Zhu M; Swaminathan A; Humphreys WG
Drug Metab Dispos; 2006 Feb; 34(2):267-80. PubMed ID: 16280454
[TBL] [Abstract][Full Text] [Related]
10. Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride.
Prakash C; O'Donnell J; Khojasteh-Bakht SC
Drug Metab Dispos; 2007 Jul; 35(7):1071-80. PubMed ID: 17431029
[TBL] [Abstract][Full Text] [Related]
11. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.
Frohna P; Lu J; Eppler S; Hamilton M; Wolf J; Rakhit A; Ling J; Kenkare-Mitra SR; Lum BL
J Clin Pharmacol; 2006 Mar; 46(3):282-90. PubMed ID: 16490804
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
Prakash C; Kamel A; Gummerus J; Wilner K
Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
[TBL] [Abstract][Full Text] [Related]
14. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals.
Ling J; Fettner S; Lum BL; Riek M; Rakhit A
Anticancer Drugs; 2008 Feb; 19(2):209-16. PubMed ID: 18176118
[TBL] [Abstract][Full Text] [Related]
15. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans.
Vermeir M; Naessens I; Remmerie B; Mannens G; Hendrickx J; Sterkens P; Talluri K; Boom S; Eerdekens M; van Osselaer N; Cleton A
Drug Metab Dispos; 2008 Apr; 36(4):769-79. PubMed ID: 18227146
[TBL] [Abstract][Full Text] [Related]
16. Absorption, metabolism, and excretion of [
Ye YE; Woodward CN; Narasimhan NI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
[TBL] [Abstract][Full Text] [Related]
17. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy.
Colizza K; Awad M; Kamel A
Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.
Weinz C; Schwarz T; Kubitza D; Mueck W; Lang D
Drug Metab Dispos; 2009 May; 37(5):1056-64. PubMed ID: 19196845
[TBL] [Abstract][Full Text] [Related]
19. The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans.
Mannens GS; Hendrickx J; Janssen CG; Chien S; Van Hoof B; Verhaeghe T; Kao M; Kelley MF; Goris I; Bockx M; Verreet B; Bialer M; Meuldermans W
Drug Metab Dispos; 2007 Apr; 35(4):554-65. PubMed ID: 16936066
[TBL] [Abstract][Full Text] [Related]
20. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]